1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co. KGaA

DWRKF
Drägerwerk AG & Co. KGaAUS flagOther OTC
543.70
USD
- -
- -
1.75BMarket Cap
Drägerwerk AG & Co. KGaA
DWRKF
(Other OTC)

Recent

price

543.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
1,911
2,177
2,256
2,373
2,374
2,435
2,609
2,524
2,572
2,595
2,781
3,406
3,328
3,045
3,374
3,371
3,361
Sales/Revenue/Turnover
4.11
9.43
9.85
9.84
8.73
7.28
3.07
6.12
5.95
2.47
2.97
12.09
8.34
-2.62
5.46
5.34
4.27
Operating Margin (%)
66
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
32
91
128
139
120
105
33
82
99
34
33
250
154
-65
110
124
100
Net Income, GAAP
34.14
31.82
30.81
31.28
32.4
31.84
32.78
32.66
31.08
32.44
31.77
30.62
34.81
- -
20.75
28.87
29.29
Effective Tax Rate (%)
1.7
4.17
5.67
5.86
5.07
4.29
1.26
3.25
3.83
1.32
1.2
7.34
4.63
-2.12
3.27
3.69
2.97
Profit Margin (%)
451
542
690
631
670
703
585
723
728
753
763
994
1,057
684
848
906
745
Working Capital
552
318
367
284
260
178
147
198
146
132
200
239
270
242
340
287
234
LT Debt
394
637
730
730
816
897
946
1,004
1,068
1,081
1,076
1,034
1,260
1,319
1,409
1,537
1,466
Total Equity
4.61
11.46
12.61
13
11.67
9.82
4.14
7.78
7.81
3.17
4.09
20.16
11.64
- -
7.89
6.48
5.21
Return on Invested Capital (%)
7.56
16.58
20.9
17.76
14.54
12.59
4.77
9.65
10.81
4.17
4.33
24.74
14.66
- -
8.98
8.89
6.55
Return on Capital (%)
- -
- -
46.12
26.57
20.61
16.07
4.93
11.72
12.68
4.13
4.02
31.48
17.75
-6.49
10.34
10.58
8.48
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
109
115
213
LT Borrowings
204
154
154
LT Finance Leases
83
- -
79
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,885
1,852
1,756
Cash, Cash Equivalents & STI
248
291
219
Accounts Receivable, Net
788
630
623
Inventories
654
713
706
Total Current Liabilities
978
1,021
1,011
Payables & Accruals
- -
- -
- -
ST Debt
109
115
213
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.73%
7.7%
9.05%
Free Cash Flow
-106.29%
-25.4%
-14.77%
Net Income, GAAP
24.37%
42.3%
12.65%
Sales/Revenue/Turnover
3.63%
4.48%
-0.08%
Total Cash Common Dividend
- -
- -
800.79%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
761
771
789
1,053
3,374
2024
736
785
775
1,076
3,371
2025
730
780
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
CellaVision AB (publ) (CEVI.ST)
Perpetua Medical AB (publ) (PERP-B.ST)
Therma Bright Inc. (TBRIF)
IsoPlexis Corporation (ISO)
APT Medical Inc. (688617.SS)
Respiri Limited (RSHUF)
Business
Drägerwerk AG & Co. KGaA develops, manufactures and markets medical and safety technology products worldwide; core offerings in the medical division include ventilators such as Evita V800, V600 and Babylog VN800, anesthesia workstations like Atlan A350/A350XL and Polaris surgical lights, neonatal care solutions including Babyroo TN300 and BiliPredics software, as well as patient monitoring and respiratory support systems for acute care in hospitals; in the safety division, products comprise stationary and mobile gas detection systems like X-am 5800 and X-am 2800, personal protective equipment including self-contained breathing apparatus such as PSS AirBoss and BG ProAir Mining Edition, alcohol and drug testing devices like Alcotest 7000 and 6000, and respiratory protection for fire services, mining, oil and gas, chemical industry and defense sectors, complemented by services, rentals, training and digital solutions. The family-owned company, founded in 1889 and headquartered in Lübeck, Germany, employs over 16,000 people, operates sales and service locations in around 50 countries across Europe, Americas, Africa, Asia and Australia, and generated net sales of EUR 3.4 billion in fiscal year 2024. Recent developments include strong order intake growth in the first nine months of 2025 with net sales up and robust earnings, launches of ProAir respiratory protection and Alcotest 7000 in 2025, Polaris surgical lights receiving Red Dot Best of the Best Award 2025 and Vizient Innovative Technology Designation, PSS AirBoss SCBA earning NFPA 1970:2025 certification, multiple products achieving U.S. government Authority to Operate under Risk Management Framework, CMMC Level 2 cybersecurity certification, VHA contract for surgical lighting, and R&D investment of up to EUR 350 million planned for 2025.